Figure 3. Immunologic studies comparing ZAP10 with other daclizumab-treated patients with multiple sclerosis.
(A, B) Immunologic studies were performed at pretreatment baseline and after 6.5 months of daclizumab therapy, as reported perviously.2,10 Data from patient ZAP10 are highlighted as thicker black lines in each panel.